Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Seeking a More Trustworthy Global Supply Chain

This article was originally published in The Gold Sheet

Executive Summary

Restoring trust: Now that suspect ingredients from China have infiltrated legitimate supply chains for glycerin, pet food and heparin, drug makers are asking what more they must do to remain confident in the integrity of their own supply chains. FDA urges them to audit more suppliers more thoroughly, while APIC's Oldenhof calls for testing and auditing API makers to build 'justified trust' and gives some tips on what to look for. Some technology approaches draw favor, such as fingerprinting facilities by examining their products. Third-party solutions to auditing excipient and API makers are promoted, though uptake has been slow.

You may also be interested in...



The Quality Lowdown: Yes, The US FDA Expects You To Heed Import Alerts And Testing Requirements

PCCA repackaged adulterated APIs, Allay failed to understand processes, ShangRao and Mexican firms peddled subpotent, sometimes methanol-tainted ethanol.

BARDA Lays Out Vision For Next Pandemic: Vaccines For The US Within 130 Days

Federal agency seeks dialogue with industry on how to enable surge capacity for pandemic vaccines without cutting back on other production.One key factor: workforce development.

As Emergent Partnership Dissolves, BARDA Looks To Revamp Post-COVID Pandemic Preparedness

BARDA terminates CIADM contract in wake of vaccine cross-contamination incident, begins discussion with industry about next steps for rapid pandemic response capabilities.

UsernamePublicRestriction

Register

PS000233

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel